Contributions of de novo variants to systemic lupus erythematosus.
Jonas Carlsson AlmlöfSara NystedtAikaterini MechtidouDag LeonardMaija-Leena ElorantaGiorgia GrossoChristopher SjöwallAnders A BengtssonAndreas JönsenIva GunnarssonElisabet SvenungssonLars RönnblomJohanna K SandlingAnn-Christine SyvänenPublished in: European journal of human genetics : EJHG (2020)
By performing whole-genome sequencing in a Swedish cohort of 71 parent-offspring trios, in which the child in each family is affected by systemic lupus erythematosus (SLE, OMIM 152700), we investigated the contribution of de novo variants to risk of SLE. We found de novo single nucleotide variants (SNVs) to be significantly enriched in gene promoters in SLE patients compared with healthy controls at a level corresponding to 26 de novo promoter SNVs more in each patient than expected. We identified 12 de novo SNVs in promoter regions of genes that have been previously implicated in SLE, or that have functions that could be of relevance to SLE. Furthermore, we detected three missense de novo SNVs, five de novo insertion-deletions, and three de novo structural variants with potential to affect the expression of genes that are relevant for SLE. Based on enrichment analysis, disease-affecting de novo SNVs are expected to occur in one-third of SLE patients. This study shows that de novo variants in promoters commonly contribute to the genetic risk of SLE. The fact that de novo SNVs in SLE were enriched to promoter regions highlights the importance of using whole-genome sequencing for identification of de novo variants.
Keyphrases
- systemic lupus erythematosus
- copy number
- disease activity
- genome wide
- end stage renal disease
- dna methylation
- ejection fraction
- gene expression
- chronic kidney disease
- newly diagnosed
- transcription factor
- metabolic syndrome
- patient reported outcomes
- mental health
- autism spectrum disorder
- high resolution
- single molecule
- human health
- risk assessment